BioSpace News Archive

DaVita Inc. announced that it has commenced a modified “Dutch auction” tender offer for shares of its common stock for an aggregate purchase price of up to $1.0 billion at a price per share of not less than $77.00 and not more than $88.00.

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD002.

Salman Arif, the CEO of The Health Bank (THB) Global , announced today that the company is partnering with Nanotronics Health, LLC, to distribute nHale TM , a non-invasive ventilator. It will be distributed in the Middle East, North Africa and South Asia (MENASA) region. To support non-invasive respiratory therapy in the region, The Health Bank will also train medical professionals to operate the device.

GNI Group Ltd., a commercial-stage biopharmaceutical company, announced positive results from the initial analysis of Phase II clinical trial of the F351 drug candidate for liver fibrosis.

Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits

CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, announced its publication of the 7×21 CAR-T technology in CLINICAL CANCER RESEARCH.

United Therapeutics Corporation announced that the U.S. Food and Drug Administration accepted for review the supplemental New Drug Application for Tyvaso® Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease.

Seneca Therapeutics, Inc. announced the appointment of James M. Hussey as Chief Executive Officer and member of the Board of Directors.

Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker Results

Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA™ Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA